Status:
UNKNOWN
Study on Biomarkers to Predict the Efficacy of IL-4R Monoclonal Antibody for Chronic Rhino-sinusitis With Polyps
Lead Sponsor:
Beijing Tongren Hospital
Conditions:
Chronic Rhino-sinusitis
IL-4R
Eligibility:
All Genders
18+ years
Brief Summary
The prevalence of chronic rhinosinusitis in China is about 8%, and some patients still suffer from recurrences after surgery and drug treatment. Monoclonal antibody is considered to be a new drug stra...
Detailed Description
The prevalence of chronic rhinosinusitis in China is about 8%, and some patients still suffer from recurrences after surgery and drug treatment. Monoclonal antibody is considered to be a new drug stra...
Eligibility Criteria
Inclusion
- Patients enrolled in NCT04805398.
Exclusion
- Patients not enrolled in NCT04805398.
Key Trial Info
Start Date :
June 17 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2023
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT05428410
Start Date
June 17 2022
End Date
June 1 2023
Last Update
June 23 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 100000